Introduction
============

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the US, with an estimated prevalence of 25 million and an annual death rate of 124,477.[@b1-copd-9-775],[@b2-copd-9-775] Maintenance therapies for COPD recommended by clinical guidelines include long-acting β~2~-adrenergic agonists (LABAs) alone, inhaled corticosteroid (ICS)--LABA combinations, and anticholinergic agents.[@b3-copd-9-775]

Budesonide--formoterol combination (BFC) therapy was approved in the US in 2009 for the maintenance treatment of airflow obstruction in COPD patients.[@b4-copd-9-775] Tiotropium bromide inhalation powder, approved for COPD treatment in the US in 2004, is indicated for long-term, once-daily maintenance treatment of bronchospasm associated with COPD; it is also indicated to reduce COPD exacerbations.[@b5-copd-9-775]

To date, no study has compared health care-resource utilization and costs of COPD patients prior to initiating BFC versus tiotropium. The objective of this study was to describe and evaluate demographic and clinical characteristics and health care utilization and costs in COPD patients initiating BFC or tiotropium bromide in the 12 months prior to treatment initiation.

Materials and methods
=====================

Study design, population, and data source
-----------------------------------------

This cross-sectional study employed administrative claims data to describe key characteristics of COPD patients initiating BFC or tiotropium therapy between March 1, 2009 and January 31, 2012 (intake period). Patients were identified using Generic Product Identifier codes: BFC (4420990241) and tiotropium (44100080100120). The index date was defined as the processing date of the first pharmacy claim for COPD maintenance medication, and patients were assigned to either the BFC or tiotropium group depending on their index prescription fill. The BFC group consisted of BFC initiators who received no tiotropium or ICS--LABA in the 12 months prior to the index date, and to ensure patients were initiating only one of the study medications, had no tiotropium fills within 15 days of initiating BFC therapy. Similarly, patients in the tiotropium group received neither tiotropium nor ICS--LABA in the 12 months prior to the index date, and did not fill an ICS--LABA prescription within 15 days of starting tiotropium treatment.

All study data were queried from the HealthCore Integrated Research Database, a repository of a broad spectrum of medical, pharmacy, and laboratory information on more than 46 million health plan members from across the US. The service models of the 14 commercial health plans included in the database encompass health maintenance organizations, point of service, preferred provider organizations, and indemnity plans. Throughout this study, researchers' access was limited to deidentified data to ensure patient privacy and confidentiality. Strict measures were observed to ensure full compliance with the Health Insurance Portability and Accountability Act of 1996.

Inclusion criteria
------------------

Patients had to be ≥40 years old at the index date, have COPD and at least one prescription fill for BFC or tiotropium during the intake period. COPD diagnostic criteria included the presence of at least one inpatient claim with a primary diagnosis of COPD and/or at least one emergency department (ER) claim with a COPD diagnosis and/or two other medical claims with a COPD diagnosis, including outpatient visits or inpatient visits with a nonprimary COPD diagnosis (based on the *International Classification of Diseases*, ninth revision, clinical modification \[ICD-9-CM\] diagnosis codes 491.xx, 492.xx, and 496.xx). Patients were also required to have at least 12 months of continuous health plan coverage for medical and pharmacy benefits prior to the index date.

Exclusion criteria
------------------

Excluded were patients with a diagnosis of respiratory tract cancer (larynx, trachea, pleura, or lung) during the 12-month preindex date, as indicated by the presence of two medical claims, at least 30 days apart (ICD-9-CM codes 161.xx, 162.xx, 163.xx, 231.xx, and 197.0x).

Measures
--------

Important measures in this analysis included indicators of COPD disease activity, such as use of respiratory medications (ICS, LABA, ICS--LABA combination, tiotropium, leukotriene-receptor antagonists, theophylline, roflumilast, short-acting β~2~-agonists \[SABAs\], short-acting muscarinic antagonists \[SAMAs\], SABA--SAMA combination, and oral corticosteroids \[OCS\]), prior COPD exacerbations, COPD-related health care-resource utilization (inpatient visits, ER visits, outpatient visits, and other places of service with an ICD-9-CM diagnosis code for COPD), and COPD-related procedures (chest X-rays, chest computed tomography scans, pulmonary function tests, and home oxygen use). Costs of COPD-related health care utilization and respiratory medications were also analyzed. COPD exacerbations were analyzed as a single outcome and by each individual component: COPD-related inpatient hospitalizations, ER visits, and OCS prescription fills. Other indicators of overall health status included all-cause health care-resource utilization and costs, presence of chronic comorbid conditions, and total medication use.

Statistical analysis
--------------------

The frequency and proportion of all categorical and dichotomous variables, along with odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Significant differences between the two treatment groups were analyzed with *χ*^2^ tests or Fisher's exact test when *χ*^2^ was not appropriate. Means (± standard deviations), medians, mean differences, and 95% CIs were calculated for each continuous and count variable. Student's *t*-test was used to analyze differences in mean age, γ-regression was used to analyze all health care-cost variables, and negative binomial regression was used to analyze the number of all-cause and COPD-related health care visits, prescription fills, and inpatient length of stay for patients having an inpatient visit(s). No adjustment for confounders was performed, and finally, data were not balanced or matched. All statistical analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC, USA), and *α* was set at 5%.

Results
=======

Preindex demographics and clinical characteristics
--------------------------------------------------

A total of 6,940 and 10,831 BFC- and tiotropium-initiated patients, respectively, were identified. There were some differences in demographic characteristics between the two groups of patients. COPD patients initiating BFC relative to those initiating tiotropium were younger (mean ± standard deviation age 64.3±12.1 years versus 66.9±11.8 years) and more likely to be female (54.2% versus 50.6%), respectively ([Table 1](#t1-copd-9-775){ref-type="table"}). Both groups had similar geographic distribution and health plan coverage (59.5% in the BFC and 60.7% in the tiotropium groups were in preferred provider organizations). In both treatment groups, similar proportions of patients were initiated on either medication during each year of the study period -- 2009--2012. The index treatment was prescribed by internists (26.0% and 27.1%), family/general practitioners (26.9% and 26.9%), and pulmonologists (23.1% and 26.6%) for BFC and tiotropium, respectively.

Preindex chronic comorbidities
------------------------------

During the 12 months prior to the index date, patients in the BFC group had more comorbid respiratory conditions than the tiotropium group, including asthma (24.7% versus 12.7%, OR 2.26, CI 2.09--2.44), allergic rhinitis (8.0% versus 4.1%, OR 2.04, CI 1.79--2.32), and sinusitis (10.4% versus 6.6%, OR 1.65, CI 1.48--1.84), ([Table 2](#t2-copd-9-775){ref-type="table"}). BFC-treated patients had fewer comorbid cardiovascular conditions, including myocardial infarction (4.3% versus 6.0%, OR 0.71, CI 0.62--0.82) and peripheral vascular disease (7.5% versus 9.8%, OR 0.75, CI 0.67--0.83).

Preindex respiratory medication fills
-------------------------------------

A greater proportion of BFC-treated patients had prior respiratory medication fills, including at least one fill for OCS (45.8% versus 34.6%, OR 1.60, CI 1.50--1.70), ICS (11.1% versus 8.8%, OR 1.29, CI 1.17--1.43), SABA (43.9% versus 34.8%, OR 1.47, CI 1.38--1.56), leukotriene-receptor antagonists (11.6% versus 6.0%, OR 2.05, CI 1.84--2.29), and SABA--SAMA combinations (16.5% versus 12.6%, OR 1.37, CI 1.26--1.49) ([Table 3](#t3-copd-9-775){ref-type="table"}). The higher respiratory medication use among BFC patients was likely because BFC, unlike tiotropium, is indicated for asthma and more likely to be prescribed to patients with asthma.

Preindex COPD-related health care-resource utilization
------------------------------------------------------

A significantly smaller proportion of BFC-treated patients had COPD-related outpatient visits (68.4% BFC versus 74.4% tiotropium, OR 0.75, CI 0.70--0.80), and the mean number of visits was smaller for BFC patients (4.1 versus 4.6, mean difference 0.52, CI 0.33--0.70). A greater proportion of BFC-treated patients had outpatient visits that were associated with an OCS or antibiotic prescription fill (44.0% BFC versus 33.0% tiotropium, OR 1.59, CI 1.49--1.69). As shown in [Figure 1](#f1-copd-9-775){ref-type="fig"}, the proportions of COPD-related inpatient hospitalizations were generally equal between the two groups, while ER visits were slightly more common in tiotropium patients (7.7% BFC versus 8.6% tiotropium, OR 0.89, CI 0.80--0.99). As indicated in [Figure 2](#f2-copd-9-775){ref-type="fig"}, there were only small differences between the two groups in the utilization of COPD-related procedures: chest X-rays (71.9% BFC versus 73.7% tiotropium, OR 0.92, CI 0.86--0.98), chest computed tomography scans (27.2% BFC versus 29.5% tiotropium, OR 0.89, CI 0.84--0.96), oximetry (13.4% BFC versus 11.9% tiotropium, OR 1.15, CI 1.05--1.25), and home oxygen use (8.9% BFC versus 10.0% tiotropium, OR 0.87, CI 0.78--0.97), with no difference in pulmonary function tests (55.9% BFC versus 55.4% tiotropium, OR 1.02, CI 0.96--1.08).

Preindex COPD exacerbation rates by age-group
---------------------------------------------

In the year prior to initiation of COPD maintenance medication, patients new to tiotropium were less likely to have a COPD exacerbation compared with those new to BFC (50.2% BFC versus 40.4% tiotropium). The difference in COPD exacerbation rates was driven by differences in OCS use, while COPD-related inpatient hospitalization and ER visits were comparable between the groups. Similar results were observed when exacerbation rates were calculated for those \<65 and ≥65 years of age ([Table 4](#t4-copd-9-775){ref-type="table"}). In both treatment groups, patients \<65 years old had higher preindex rates of COPD exacerbations compared to those ≥65 years old. Age-adjusted exacerbation-rate differences were more pronounced within BFC patients (53.6% of patients aged \<65 years with at least one prior exacerbation compared with 46.3% of patients ≥65) than tiotropium patients (42.8% versus 38.4%).

Preindex COPD and all-cause-related health care costs
-----------------------------------------------------

In the year prior to initiation of COPD maintenance medication, patients new to BFC had lower total all-cause health care costs compared with patients new to tiotropium (\$17,259 versus \$17,926, mean difference −\$667, CI −\$1,254 to −\$58). This cost difference was largely due to lower all cause inpatient costs for the BFC group (\$7,459 versus \$8,599, mean difference −\$1,140, CI −\$1,712 to −\$521) ([Figure 3](#f3-copd-9-775){ref-type="fig"}). BFC-treated patients had lower total COPD-related health care costs (\$1,718 versus \$1,930, mean difference −\$213, CI −\$302 to −\$118), primarily due to lower COPD-related inpatient costs (\$627 versus \$767, mean difference −\$140, CI −\$190 to −\$85) ([Figure 4](#f4-copd-9-775){ref-type="fig"}).

Discussion
==========

Therapeutic guidelines recommend the treatment and prevention of exacerbations as the main goal of COPD management.[@b3-copd-9-775],[@b6-copd-9-775] With the availability of different therapeutic options, the decision to initiate COPD maintenance medication is often determined by presenting symptoms, clinical history, and the risk assessment of future COPD exacerbations.[@b7-copd-9-775]--[@b9-copd-9-775] This study is the first to assess differences in characteristics of COPD patients before they initiated BFC or tiotropium using claims data from a large geographically diverse population.

As a result, there is a dearth of comparable study data in the literature with which to evaluate our results. While studies have compared patients who initiated COPD-controller medications, they have not studied BFC relative to tiotropium, nor have they focused on the baseline period, before patients are indexed on maintenance therapy.[@b10-copd-9-775],[@b11-copd-9-775] While there are studies that have incorporated one of the agents we assessed,[@b12-copd-9-775] it would appear that no published study to date has compared preindex demographics, clinical characteristics, chronic comorbidities, respiratory medication fill, COPD-related health care utilization, exacerbation rates, and COPD and all-cause health care costs during the preindex period for patients initiating BFC and tiotropium as maintenance therapy.

Current study results indicate that COPD patients who initiate maintenance therapy with BFC may be different than those who initiate tiotropium. Patients who initiated BFC in this study had a higher prevalence of chronic respiratory conditions and higher utilization of respiratory medication at baseline. BFC initiators had a higher percentage of COPD exacerbations in the 12 months preindex for both the \<65- and ≥65-year age-groups compared with patients indexing on tiotropium. The majority of COPD exacerbations were captured by OCS prescription fills, which contributed most to the differences observed between the groups.

BFC is also indicated for asthma, which likely contributes to the higher proportion of patients in the BFC group with a prior asthma diagnosis compared to tiotropium. Greater respiratory disease comorbidities in the BFC group also likely accounts for the increased utilization of respiratory medications preindex, including but not limited to OCS. Such comorbid conditions as allergic rhinitis, sinusitis, and gastroesophageal reflux disease were also more prevalent in the BFC-treated population. Conversely, the observed higher overall health care costs among tiotropium initiators may be due to their older age and the higher prevalence of comorbid cardiovascular disease.

Among the proxy measures for exacerbations in this study were COPD-related inpatient hospitalizations and ER visits and OCS fills. While antibiotic usage may also be used as a proxy for COPD exacerbations, it is not specific to COPD. In this analysis, COPD-related visits with OCS or antibiotic prescription fills occurring within 10 days of the visit were also captured. This broadened definition of an exacerbation did not result in the inclusion of additional patients who were not already captured by the initial definition. Prior exacerbations are predictive of future exacerbations; as a consequence,[@b13-copd-9-775],[@b14-copd-9-775] it would be informative to control for prior exacerbations in analyses of postindex exacerbation rates in future comparative effectiveness studies.[@b15-copd-9-775]

Limitations
-----------

This study adds new insights on the clinical characteristics of COPD patients prior to initiation of COPD maintenance medication. The interpretation of findings should be within the context of limitations inherent to the use of administrative claims databases.[@b16-copd-9-775]--[@b22-copd-9-775] Primarily, COPD-related health care-resource utilization is based on claims diagnosis; however, the actual visit may be due to routine follow-up and monitoring.

Claims data do not include clinical indicators of COPD disease severity (ie, symptoms or lung-function data), and thus only measures of disease activity were analyzed (ie, COPD-related health care utilization and costs). Smoking status, a primary cause of COPD, is also unknown in this data source. Because administrative claims data may be subject to incorrect or rule-out diagnoses, the diagnostic criteria for COPD required more than one claim containing a diagnosis of COPD for most cases, the exceptions being an inpatient hospitalization with a primary COPD diagnosis or ER visit with a COPD diagnosis.

For the pharmacy claims, a prescription-fill date was recorded as the beginning date of treatment, which might not have been the actual date a patient started therapy. Patients aged 65 years and older were underrepresented in the database used for this study. Overall, these findings may have limited applicability beyond similar managed care patient populations.

Conclusion
==========

Patients initiating BFC or tiotropium therapy had important differences prior to the start of treatment. COPD patients initiating BFC had a higher proportion of COPD exacerbations before starting controller therapy compared with tiotropium initiators, which may be indicative of more severe disease or attributable to a higher prevalence of comorbid respiratory disorders in this group. The higher overall health care costs among tiotropium-treated patients could be a reflection of a greater degree of cardiovascular disease within this group. A much higher prevalence of asthma in the BFC population was observed, which may have influenced such characteristics as other comorbid respiratory conditions and concomitant respiratory medication use. Such differences among patient groups must be considered in outcome studies evaluating the comparative effectiveness of different therapies, as they may influence patients' probability of initiating and benefiting from a particular treatment.
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![COPD-related resource utilization by service type during 12-month preindex period.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; BFC, budesonide--formoterol combination; hosp, hospitalization; ER, emergency room; OCS, oral corticosteroid.](copd-9-775Fig1){#f1-copd-9-775}

![COPD-related resource utilization by procedure during 12-month preindex period.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; BFC, budesonide--formoterol combination; CT, computed tomography; func, function; rehab, rehabilitation.](copd-9-775Fig2){#f2-copd-9-775}

![All-cause health care costs during 12-month preindex period.\
**Abbreviations:** BFC, budesonide--formoterol combination; ER, emergency room; USD, United States dollar.](copd-9-775Fig3){#f3-copd-9-775}

![COPD-related health care costs during 12-month preindex period.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; BFC, budesonide--formoterol combination; ER, emergency room; USD, United States dollar.](copd-9-775Fig4){#f4-copd-9-775}

###### 

Baseline demographic characteristics and prescribing physician type

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                 Group 1: BFC without previous tiotropium or\   Group 2: tiotropium without previous tiotropium or\   Group 1 versus group 2                                   
                                 ICS--LABA                                      ICS--LABA                                                                                                      
  ------------------------------ ---------------------------------------------- ----------------------------------------------------- ------------------------ ------- ------- ------- ------- ----------
                                                                                                                                                                                               

  All patients                   6,940                                                                                                10,831                                                   

  **Prescriber specialty**                                                                                                                                                                     

  Allergist/immunologist         170                                            2.5%                                                  106                      1.0%    2.54    1.99    3.24    \<0.0001

  Pulmonologist                  1,604                                          23.1%                                                 2,882                    26.6%   0.83    0.77    0.89    \<0.0001

  Cardiologist                   127                                            1.8%                                                  239                      2.2%    0.83    0.67    1.03    0.0846

  Internal medicine              1,802                                          26.0%                                                 2,939                    27.1%   0.94    0.88    1.01    0.0854

  Family/general practitioner    1,867                                          26.9%                                                 2,916                    26.9%   1.00    0.93    1.07    0.9758

  Nonphysician                   295                                            4.3%                                                  461                      4.3%    1.00    0.86    1.16    0.9857

  Other specialty                131                                            1.9%                                                  191                      1.8%    1.07    0.86    1.34    0.5449

  Unknown                        944                                            13.6%                                                 1,097                    10.1%   1.40    1.27    1.53    \<0.0001

  **Index year (n, %)**                                                                                                                                                                        

  2009                           2,216                                          31.9%                                                 3,649                    33.7%   0.92    0.87    0.99    0.0150

  2010                           2,579                                          37.2%                                                 3,764                    34.8%   1.11    1.04    1.18    0.0011

  2011                           1,971                                          28.4%                                                 3,225                    29.8%   0.94    0.88    1.00    0.0493

  2012                           174                                            2.5%                                                  193                      1.8%    1.42    1.15    1.74    0.0009

  **Age (n, %)**                                                                                                                                                                               

  40--49 years                   820                                            11.8%                                                 761                      7.0%    1.77    1.60    1.97    \<0.0001

  50--59 years                   1,828                                          26.3%                                                 2,436                    22.5%   1.23    1.15    1.32    \<0.0001

  60--64 years                   1,078                                          15.5%                                                 1,681                    15.5%   1.00    0.92    1.09    0.9816

  65+ years                      3,214                                          46.3%                                                 5,953                    55.0%   0.71    0.67    0.75    \<0.0001

  Mean ± SD                      64.3                                           12.1                                                  66.9                     11.8    −2.67   −3.03   −2.30   \<0.0001

  **Sex (n, %)**                                                                                                                                                                               

  Male                           3,178                                          45.8%                                                 5,349                    49.4%   1.16    1.09    1.23    \<0.0001

  Female                         3,762                                          54.2%                                                 5,482                    50.6%   0.87    0.82    0.92    \<0.0001

  **Health plan type (n, %)**                                                                                                                                                                  

  HMO                            1,321                                          19.0%                                                 2,416                    22.3%   0.82    0.76    0.88    \<0.0001

  PPO                            4,128                                          59.5%                                                 6,577                    60.7%   0.95    0.89    1.01    0.0987

  CDHP                           198                                            2.9%                                                  246                      2.3%    1.26    1.05    1.53    0.0153

  Other commercial               1,293                                          18.6%                                                 1,592                    14.7%   1.33    1.23    1.44    \<0.0001

  **Geographic region (n, %)**                                                                                                                                                                 

  Northeast                      1,227                                          17.7%                                                 2,360                    21.8%   0.77    0.71    0.83    \<0.0001

  Midwest                        2,766                                          39.9%                                                 4,051                    37.4%   1.11    1.04    1.18    0.0010

  South                          1,979                                          28.5%                                                 2,895                    26.7%   1.09    1.02    1.17    0.0092

  West                           968                                            13.9%                                                 1,525                    14.1%   0.99    0.91    1.08    0.8050
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Chi-square test odds ratio was used for categorical variables, and Student's *t*-test difference in means used for continuous variables. Statistical comparisons compared group 1 to group 2 (reference group), ie, mean difference = mean (group 1) -- mean (group 2), and odds ratio = odds (group 1)/odds (group 2).

**Abbreviations:** BFC, budesonide--formoterol; ICS, inhaled corticosteroid; LABA, long-acting β~2~-adrenergic agonist; SD, standard deviation; CI confidence interval; HMO, health maintenance organization; PPO, preferred provider organization; CDHP, consumer-driven health plan.

###### 

Comorbid conditions during the 12-month preindex period

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                             Group 1: BFC without previous tiotropium or\   Group 2: tiotropium without previous tiotropium or\   Group 1 versus group 2                                
                                                             ICS--LABA                                      ICS--LABA                                                                                                   
  ---------------------------------------------------------- ---------------------------------------------- ----------------------------------------------------- ------------------------ ------- ------ ------ ------ ----------
  Number of patients                                         6,940                                                                                                10,831                                                

  **Comorbid conditions (n, % for each comorbidity)**                                                                                                                                                                   

  Hypertension                                               4,092                                          59.0%                                                 6,552                    60.5%   0.94   0.88   1.00   0.0423

  Dyslipidemia                                               3,049                                          43.9%                                                 4,801                    44.3%   0.98   0.93   1.05   0.6070

  Asthma                                                     1,716                                          24.7%                                                 1,377                    12.7%   2.26   2.09   2.44   \<0.0001

  Diabetes mellitus                                          1,630                                          23.5%                                                 2,404                    22.2%   1.08   1.00   1.16   0.0449

  Other coronary artery disease                              1,557                                          22.4%                                                 3,038                    28.1%   0.74   0.69   0.80   \<0.0001

  Other lung diseases                                        1,187                                          17.1%                                                 2,086                    19.3%   0.87   0.80   0.94   0.0003

  Congestive heart failure                                   917                                            13.2%                                                 1,755                    16.2%   0.79   0.72   0.86   \<0.0001

  GERD                                                       888                                            12.8%                                                 1,220                    11.3%   1.16   1.05   1.27   0.0021

  Sleep apnea                                                781                                            11.3%                                                 1,087                    10.0%   1.14   1.03   1.25   0.0098

  Sinusitis                                                  720                                            10.4%                                                 711                      6.6%    1.65   1.48   1.84   \<0.0001

  Allergic rhinitis                                          558                                            8.0%                                                  446                      4.1%    2.04   1.79   2.32   \<0.0001

  Anxiety                                                    536                                            7.7%                                                  716                      6.6%    1.18   1.05   1.33   0.0047

  Peripheral vascular disease/atherosclerosis                518                                            7.5%                                                  1,056                    9.8%    0.75   0.67   0.83   \<0.0001

  Stroke, TIA, or cerebrovascular disease                    477                                            6.9%                                                  971                      9.0%    0.75   0.67   0.84   \<0.0001

  Morbid obesity[†](#tfn4-copd-9-775){ref-type="table-fn"}   439                                            6.3%                                                  498                      4.6%    1.40   1.23   1.60   \<0.0001

  Osteoporosis                                               322                                            4.6%                                                  614                      5.7%    0.81   0.71   0.93   0.0027

  Myocardial infarction                                      299                                            4.3%                                                  645                      6.0%    0.71   0.62   0.82   \<0.0001
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Odds ratio from Pearson's *χ*^2^ test, odds ratio = odds (group 1)/odds (group 2);

defined using ICD-9-CM diagnosis (BMI ≥30).

**Abbreviations:** BFC, budesonide--formoterol; BMI, body mass index; ICS, inhaled corticosteroid; LABA, long-acting β~2~-adrenergic agonist; CI confidence interval; GERD, gastroesophageal reflux disease; TIA, transient ischemic attack; ICD-9-CM, International Classification of Diseases, ninth revision, clinical modification.

###### 

Prior medication use during the 12-month preindex period

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                Group 1: BFC without previous tiotropium or\   Group 2: tiotropium without previous tiotropium or\   Group 1 versus group 2                                
                                ICS--LABA                                      ICS--LABA                                                                                                   
  ----------------------------- ---------------------------------------------- ----------------------------------------------------- ------------------------ ------- ------ ------ ------ ----------
  Number of patients            6,940                                                                                                10,831                                                

  **Respiratory medications**                                                                                                                                                              

  Nebulizer treatment           1,140                                          16.4%                                                 1,189                    11.0%   1.59   1.46   1.74   \<0.0001

  ICS monotherapy use           771                                            11.1%                                                 957                      8.8%    1.29   1.17   1.43   \<0.0001

  LABA monotherapy use          187                                            2.7%                                                  244                      2.3%    1.20   0.99   1.46   0.0618

  LTRA monotherapy use          802                                            11.6%                                                 648                      6.0%    2.05   1.84   2.29   \<0.0001

  Theophylline use              145                                            2.1%                                                  181                      1.7%    1.26   1.01   1.57   0.0427

  SABA                          3,044                                          43.9%                                                 3,764                    34.8%   1.47   1.38   1.56   \<0.0001

  SAMA                          282                                            4.1%                                                  407                      3.8%    1.09   0.93   1.27   0.3031

  SABA--SAMA combination use    1,147                                          16.5%                                                 1,367                    12.6%   1.37   1.26   1.49   \<0.0001

  OCS monotherapy use           3,178                                          45.8%                                                 3,744                    34.6%   1.60   1.50   1.70   \<0.0001
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Odds ratio from Pearson's *χ*^2^ test, odds ratio = odds (group 1)/odds (group 2).

**Abbreviations:** BFC, budesonide--formoterol; CI, confidence interval; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LTRA, leukotriene receptor antagonist; SABA, short-acting β~2~-agonist; SAMA, short-acting muscarinic antagonist; OCS, oral corticosteroid.

###### 

COPD exacerbation rates during 12-month preindex period by age-group

                                   BFC     Tiotropium                                                                            
  -------------------------------- ------- ------------ ------- ------- ------- ------- -------- ------- ------- ------- ------- -------
  Total number of patients         6,940                3,726           3,214           10,831           4,878           5,953   
  With prior COPD exacerbation     3,483   50.2%        1,996   53.6%   1,487   46.3%   4,375    40.4%   2,088   42.8%   2,287   38.4%
  COPD inpatient hospitalization   491     7.1%         220     5.9%    271     8.4%    763      7.0%    299     6.1%    464     7.8%
  COPD ER visit                    535     7.7%         307     8.2%    228     7.1%    929      8.6%    423     8.7%    506     8.5%
  OCS use                          3,178   45.8%        1,855   49.8%   1,323   41.2%   3,744    34.6%   1,827   37.5%   1,917   32.2%

**Notes:** COPD exacerbation defined as inpatient hospitalization with primary diagnosis for COPD, ER visit with any diagnosis for COPD, or prescription fill for OCS.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; BFC, budesonide--formoterol; ER, emergency room; OCS, oral corticosteroid.
